Open-label extension for Alzheimer's study completers
Part of Brain & nervous system, Mental health clinical trials.
This trial continues treatment for people who finished the earlier SNK01-AD01 study. It tests a personalized cell therapy (SNK01) to see if ongoing treatment is safe and helpful for Alzheimer's disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your legal representative must agree to the study in writing.
- You must have a reliable study partner (like a family member) who can help with visits and assessments.
- You must have already completed the earlier SNK01-AD01 study.
- Your doctor must think it's safe for you to continue.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
This trial provides continued access to an investigational drug (TRx0237) for people with early or mild-moderate Alzheimer's disease. It aims to see if long-term use is safe and beneficial.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This study is a follow-up for people who already received one dose of an experimental stem-cell treatment (called RB-ADSC) for a brain condition. It tests whether giving additional doses through a small tube in the brain is safe and tolerable. If you did well in the first study, this might be an option for continued treatment.
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
This program provides access to an investigational drug called TB006 for people with Alzheimer's disease or related dementias who have run out of standard treatment options. It aims to see if the drug is safe and helpful in a real-world setting.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.